Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lorenzo Rizzo
Observed name:
RIZZO, LORENZO
Institution:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Observed institutions:
University of Padua,
Policlinico Umberto I,
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma,
Sapienza University of Rome
show all 6
ORCID:
0000-0002-8778-8317
Observed ORCID:
0000-0002-8778-8317
OpenAlex ID:
A5029714829
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
2023
·
Esther Natalie Oliva
, Marta Riva
, et al.
·
Journal of Clinical Oncology
·
42
PDF
Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation
2015
·
Salvatore Gattillo
, Sarah Marktel
, et al.
·
Transfusion
·
36
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life
2019
·
Matteo Molica
, Gioia Colafigli
, et al.
·
Annals of Hematology
·
15
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/hypomethylating agents
2024
·
Sabine Kayser
, Khaled Sanber
, et al.
·
Haematologica
·
13
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice
2019
·
Emilia Scalzulli
, Matteo Molica
, et al.
·
Annals of Hematology
·
13
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
2021
·
Emilia Scalzulli
, Giovanni Caocci
, et al.
·
Annals of Hematology
·
12
Indomethacin is an effective treatment in adults and children with bone Langerhans cell histiocytosis (LCH)
2020
·
Daniela De Benedittis
, Sara Mohamed
, et al.
·
British Journal of Haematology
·
12
PDF
Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia
2020
·
Fiorina Giona
, Francesco Malaspina
, et al.
·
British Journal of Haematology
·
10
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an “Old-fashioned” Drug be Effective?
2023
·
Marta Riva
, Alessandro Bosi
, et al.
·
HemaSphere
·
9
Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late‐stage erythropoiesis
2023
·
Bruno Fattizzo
, Francesco Versino
, et al.
·
European Journal Of Haematology
·
9
PDF
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib
2019
·
Laura Cesini
, Ida Carmosino
, et al.
·
Oncology Research and Treatment
·
8
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
2022
·
Alessia Campagna
, Daniela De Benedittis
, et al.
·
Journal of Clinical Medicine
·
7
PDF
Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
2022
·
Monica Bocchia
, Angelo Michele Carella
, et al.
·
Pharmacogenomics and Personalized Medicine
·
7
PDF
Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
2024
·
Rosa Greco
, Silvia Imbergamo
, et al.
·
Blood
·
3
Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes: a second honeymoon?
2021
·
Bruno Fattizzo
, Lorenzo Rizzo
, et al.
·
British Journal of Haematology
·
3
PDF
Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience
2020
·
Marta Riva
, Lorenzo Rizzo
, et al.
·
Blood
·
3
Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
2024
·
Erika Borlenghi
, Lorenzo Masina
, et al.
·
Blood
·
2
Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
2022
·
Roberto Latagliata
, Gianluca Cristiano
, et al.
·
Blood
·
2
Luspatercept for the treatment of transfusion-dependent anemia in patients with myelodysplastic neoplasms with del5q, refractory/resistant/intolerant to prior treatments (QOL-ONE Phoenix)
2025
·
Esther Natalie Oliva
, Marta Riva
, et al.
·
Blood
·
1
Association of Glasdegib + Low-Dose Cytarabine (AraC)) in the Real-Life Treatment of Very Frail Elderly Acute Myeloid Leukemias (AML) Patients
2024
·
Ilaria Tanasi
, Antonella Bruzzese
, et al.
·
Blood
·
1
PDF
Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept
2023
·
Bruno Fattizzo
, Alfredo Marchetti
, et al.
·
American Journal of Hematology
·
1
Pb2004: Chronic Myelomonocytic Leukemia and Concomitant Monoclonal Gammopathy: a Multicentre Retrospective Study of Clinical Characteristics, Prevalence and Outcome
2023
·
Elisa Diral
, Gregorio Maria Bergonzi
, et al.
·
HemaSphere
·
1
Specific Guidelines Including Multidisciplinary Approach Is Critical of Management of Langerhans Cell Histiocytosis in Adults
2019
·
Lorenzo Rizzo
, Michelina Santopietro
, et al.
·
Blood
·
1
Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome
2018
·
Francesco Malaspina
, Maria Caterina Putti
, et al.
·
Blood
·
1
Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice
2018
·
Emilia Scalzulli
, Matteo Molica
, et al.
·
Blood
·
1
Show more works
View as search
Works count:
41
Citation count:
213
H-index:
9
I10-index:
8
Year
Topic
Type